Dong-A ST's antibacterial drug Sivextro achieved sales of about 29 billion won ($23.9 million) in the U.S. last year, according to the 2021 performance data released Tuesday by Nabriva Therapeutics, the exclusive marketer of Sivextro in the U.S.Sivextro accounted for 82 percent of Nabriva's total sa
Oscotec said it signed a technology transfer agreement with Kanaph Therapeutics to acquire the exclusive global license for the latter's KNP-502, an EP2/4 dual inhibitor for treating cancer.Under the accord, Kanaph will receive a down payment of 2 billion won ($1.6 million), various milestones and r
As Roche’s Gavreto (pralsetinib) won the regulatory nod following Lilly’s Retevmo (selpercatinib) in March, the two RET (rearranged during transfection) targeted therapies are likely to compete in the Korean market.However, for the two treatments to be used for cancer patients regardless of cancer t
BMS Korea said that Revlimid (ingredient: lenalidomide), its multiple myeloma treatment, will receive insurance benefits as a combination therapy with Velcade (Ingredient: bortezomib) and dexamethasone for treating newly diagnosed multiple myeloma patients from the next month.The Ministry of Health
Curome Bioscience, a Korean bio venture, said that it received orphan drug designation (ODD) for HK-660S, a nicotinamide adenine dinucleotide (NAD+) accelerator, from the U.S. Food and Drug Administration for treating primary sclerosing cholangitis (PSC).HK-660S is undergoing phase 2 in Korea with 2
Roche Korea and the government failed to reach an agreement over the reimbursement rate of Tecentriq (atezolizumab) for the treatment of hepatocellular carcinoma (HCC) within the negotiation deadline.Roche Korea said it was actively talking with the government to win health insurance benefits, but K
Dx&Vx signed a memorandum of understanding on industry-university-research cooperation with the Hanyang Institute of Bioscience and Biotechnology (HY-IBB) on Tuesday.Under the accord, Dx&Vx and HY-IBB will jointly operate NGS (Next Generation Sequencing) equipment of the genome core and collaborate
Menarini Korea plans to introduce a new gel-type erectile dysfunction treatment in Korea.According to the industry sources on Tuesday, Futura Medical, a U.K.-based pharmaceutical company, signed an exclusive license agreement with Menarini Korea for commercializing MED3000, a gel-type erectile dysfu
Three Korean pharmaceutical companies are speeding up U.S. clinical trials to develop a new non-alcoholic steatohepatitis (NASH) treatment.NASH develops when liver tissues have inflammation due to fat accumulated in the liver regardless of alcohol intake. The disease can worsen to become cirrhosis a
Eli Lilly is gearing up to overcome atopic dermatitis (AD) with a new biologic lebrikizumab after releasing an oral JAK inhibitor Olumiant (baricitinib).The company unveiled the results of phase 3 studies of lebrikizumab, an IL-13 inhibitor, at the 2022 American Academy of Dermatology Annual Meeting
Sandoz Korea said that it signed an exclusive sales partnership with Ilsung Pharmaceutical for the latter to market Sandoz Sugammadex Sodium Inj., a neuromuscular agent.Under the accord, Sandoz and Ilsung will supply and sell Sandoz Sugammadex Sodium Inj. to all large and general hospitals from Apri
Eli Lilly’s Janus kinase (JAK) inhibitor Olumiant (baricitinib), which recently came under safety scrutiny, demonstrated therapeutic effects on alopecia areata (AA), a study showed.On Saturday, the New England Journal of Medicine published the results of two phase 3 studies of Olumiant BRAVE-AA1 and
Roche said it confirmed the long-term efficacy and safety profile of Evrysdi (risdiplam), a treatment for spinal muscular atrophy (SMA), in a broad population of people with SMA.As the Health Insurance Review and Assessment Service (HIRA) has been reviewing reimbursement for Evrysdi for eight months
Hanmi Pharmaceutical said it would release Esomezole Plus Tab. 40/350mg, a gastroesophageal reflux disease (GORD) treatment that combined esomeprazole with magnesium hydroxide, an antacid.With the new product, Hanmi has established three types of esomeprazole – Esomezole Cap., Esomezole DR SR Cap.,
Daewoong Pharmaceutical said Monday it has submitted a new drug application (NDA) for Fexuclue, a gastroesophageal reflux disease (GERD) treatment, in the Philippines, Indonesia, and Thailand. The company prepared additional research data required by each country and applied for product approval fro
Jeil Pharmaceutical said Friday it has applied for approving Beova (ingredient: vibegron), a new drug for overactive bladder.Beova is a new drug for treating overactive bladder developed by Kyorin Pharmaceuticals in Japan. Jeil completed a phase 3 bridging clinical trial before applying for approval
SK Biopharmaceuticals said Thursday that it would double the performance in all of its business areas compared to the previous year.In an online news conference, the company’s top manager explained that major business plans for 2022 include cenobamate sales growth in the U.S., expansion into the glo
Although Korea has just approved MSD’s Lagevrio (ingredient: molnupravir) as the second oral Covid-19 treatment, attention is on how medical professionals will use it in clinical practice because of its relatively low efficacy.On Wednesday, the Ministry of Food and Drug Safety granted an emergency a
MedPacto said it appointed Dr. Timothy R. Allen, a global clinical expert, and former lead clinician at Karyopharm Therapeutics, as the executive vice president of clinical development at MedPacto Therapeutics, its U.S. offshoot.According to the company, new Vice President Allen is a clinical expert
Genexine said Thursday that it has signed a contract for the joint development and additional technology transfer with Indonesia's KG Bio for GX-E4, a long-acting biobetter candidate developed by Genexine to treat chronic kidney disease-induced anemia.The contract follows their agreement in 2015, wh